JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

Novavax (NASDAQ:NVAX) shares climbed more than 17% premarket on Monday after the long-awaited approval of its COVID-19 ...

Live Updates Live Coverage Has Ended Markets Turn Positive 1:37 pm by The stock market has managed to crawl its way back ...

Shares of vaccine makers saw an uptick in the latest trading session, with Moderna Inc (BMV:MRNA). (NASDAQ:MRNA) leading the ...

Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

Live Updates Live Coverage Updates appear automatically as they are published. Retail Earnings on Deck 10:28 am by With the ...

Novavax (NVAX) stock in focus as the U.S. FDA approves its COVID-19 vaccine Nuvaxovid for high-risk groups in the U.S. Read ...